18+ · Research Use Only · Not for Human Consumption
Regulation answer
Is NAD+ FDA approved?
No approved drug application for NAD+ exists in Drugs@FDA as of 23 September 2026, and the EMA medicines report has no record of it either. FDA Philippines has warned against one unregistered NAD+ food supplement. The drug record searches do not cover dietary supplements, which follow different rules.
Primara Labs sells some of the compounds covered here. Every figure on this page links to its source and the date it was checked.
Updated 23 September 2026
01
The drug databases
US FDA: "No record found" for NAD, nicotinamide adenine dinucleotide or nadide in Drugs@FDA. EMA: "No record found". NAD+ is not on FDA's compounding safety-risk list.
02
FDA Philippines
FDA Advisory No. 2025-0084, 30 January 2025: FDA Philippines warned the public against buying or consuming an unregistered liposomal NAD+ food supplement in capsules, for which no Certificate of Product Registration had been issued.
That advisory concerns one named oral supplement. It does not rule on injectable NAD+ or on any other product, and the verification portal could not be read to check registrations.
03
Where the research stands
The Research Desk rates NAD+ at small human studies. The human work is small: an intravenous trial in ischaemic heart failure and short studies of blood NAD levels in healthy adults, with animal studies of heart and brain injury behind them.
04
The human trial, and what was reported
In a single-centre randomised trial of 180 adults with heart failure from ischaemic heart disease, with no phase stated, ejection fraction at one month was 45.44% on NAD+ against 42.44% on placebo; differences in clinical events were not statistically significant.
In the 180-person heart-failure trial, one of 90 on NAD+ reported minor dizziness.
In a retrospective review at a commercial clinic, all 6 people given intravenous NAD+ reported stomach cramping, diarrhoea, nausea, vomiting, a faster heart rate or chest pressure during the infusion.
05
Blood levels
In a phase 0/1b randomised trial in healthy adults aged 45 to 75, an oral NAD+ formulation raised whole-blood NAD inside cells by 53% against placebo after five days; no clinical endpoint held up after correction for multiple testing.
This is general information, not legal advice.
Sources
Where every figure comes from
- US FDA record for NAD+ · checked 23 September 2026
- EMA record for NAD+ · checked 23 September 2026
- FDA Philippines Advisory 2025-0084 · checked 23 September 2026
- FDA Philippines site search, NAD+ · checked 23 September 2026
Last reviewed 23 September 2026